Michael Elliott,

Vice President, Scientific Innovation, Immunology

Michael is Vice President of Immunology Scientific Innovation at Johnson & Johnson Innovation, Boston.  He has spent much of his career in the biotech and pharmaceutical industry, working in large and small companies.

Michael’s career wtih the Johnson & Johnson Family of Companies includes 7 years at Centocor, where he led the clinical development of Centocor’s monoclonal antibody (mAb) products in immune and inflammatory disorders.  Foremost amongst these were the development and regulatory approval of the anti-TNF mAb infliximab (Remicade®) in rheumatoid arthritis, Crohn’s disease, ulcerative colitis and other inflammatory indications, and of the follow-on anti-TNF mAb, golimumab (Simponi®) in a range of rheumatic diseases.  His group also led clinical development of the first-in-class anti-IL-12/23 mAb, ustekinumab (Stelara®) for the treatment of psoriasis.

More recently, Michael served as General Manager and Site Head at TransForm Pharmaceuticals, a Johnson & Johnson company focused on high throughput drug formulation, and was a member of the Johnson & Johnson Corporate Office of Science and Technology.  In January 2012, he transitioned to the role of Janssen Entrepreneur in Residence at Polaris Partners, a Boston-based VC firm, where he managed a co-investment relationship aiming to build a portfolio of investments in early stage pharma and biotech companies.

Michael earned his medical degree (MBBS) and PhD from the University of Adelaide, Australia, and is a Fellow of the Royal Australasian College of Physicians. Michael has authored many peer-reviewed journal articles, reviews and book chapters in the field of cytokine immunology and protein therapeutics.


Michael Elliott
Michael Elliott